Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 19, 2012

Life Tech, SGC Creating Master Set of Epigenetics Antibodies

  • Life Technologies and the Structural Genomic Consortium (SGC) are partnering with antibody technology experts at the Universities of Chicago, and Toronto, to generate what they say will be the first-ever master set of high-quality epigenetic-targeting recombinant antibodies for use in disease-related research. The first 58 of 200 antibodies in development are already being made available to the scientific community.

    The partners claim the antibody set will provide a new standard, to enable more effective study of the epigenetic regulatory proteins in a wide range of disease fields. “The partnership is prepared to produce a set of 200 highly specific, highly sensitive antibodies that are validated for specific applications,” comments Aled Edwards, Ph.D., CEO and director of SGC. “These 58 now being launched are the first step toward developing the de facto standard set of quality epigenetics antibodies that researchers can use for generations to come.”

    SGC is a nonprofit organization involving 200 researchers at the University of Toronto, and University of Oxford (U.K.), together with six pharmaceutical companies: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and Takeda. 

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »